| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we have observed the phenotype about the condition of a patient of the newborn hepatitis that showing Sox17 haploinsufficiency comparative with Sox17 conditional knockout lines for liver, pancreas and gallbladder, morphologically. In addition, as a candidate of the new human disease model, we confirmed gene introduction efficiency by use of TARGATT (the transgenic mouse system which can control a copy number in site specific). We will apply it as a disease model compared with Sox17 heterozygous mouse and point mutated SHIVA mouse (Met 72 mutated to Arg; with the liver metabolism abnormality symptom).
|
